In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Future Is Non-Hormonal: Contraceptive Market Crawls Into The 21st Century

Early Stage Contraceptive Competitors Are Working On Hormone-Free Solutions

Executive Summary

Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.

You may also be interested in...



Gedeon Richter Acquires Oral Contraceptive Range From Consilient Health

Gedeon Richter has purchased a range of eight branded generic oral contraceptive drugs from Consilient Health for a consideration of over $40m, which it will now go on to market in the UK.

Finance Watch: Biopharma Reckoning Brings Restructuring Plans, Consolidation

With cash preservation in mind, Rubius will dissolve, while EQRx, Impel, Cybin and Graphite cut jobs. Meanwhile, Jounce is restructuring and it plans to merge with Redx, yet the dually troubled firms MEI Pharma and Infinity will combine, while VBL will disappear in a reverse merger with Notable Labs. 

Dobbs Decision Could Have Knock-On Effects For Wider Reproductive Healthcare Landscape

The US Supreme Court’s overturning of Roe v. Wade, which enshrined the right to an abortion in the Constitution for almost 50 years, could have consequences that extend beyond access to termination of pregnancy. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV146782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel